Value proposition

Putting public health needs at the centre of antibiotic drug development to address the crisis of AMR

The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come.

GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries.

GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018.

www.gardp.org

Antibiotic resistance, antibiotic drug development, R&D partnerships, serious bacterial infections, children’s antibiotics, sexually transmitted infections, global health, public health, pandemic preparedness, antibiotic access, sepsis and neonatal sepsis, and gonorrhoea